Literature DB >> 3740124

Suppression of aldosterone production by low-dose heparin.

R A Sherman, M C Ruddy.   

Abstract

Low-dose heparin has achieved wide use for the prevention of deep vein thrombosis. Full-dose heparin (20,000 U/day or more) has a well-documented suppressive effect on adrenal aldosterone production. To determine whether this effect may also occur with low-dose heparin, 5 healthy male volunteers were given heparin, 5,000 U subcutaneously every 12 h for 10 days, and their renin-aldosterone axis was studied. Plasma aldosterone fell from a mean of 17.2 ng/dl at baseline to 6.6 on day 5 and 4.3 on day 10. The 24-hour urinary aldosterone fell from 11.5 micrograms/day at baseline to 5.3 and 6.8 on days 4-5 and 9-10, respectively. After stimulation with furosemide (60 mg orally) and 4 h ambulation, plasma aldosterone remained suppressed on heparin: 22.4 ng/sl at baseline, 7.0 on day 5 and 6.2 ng/dl on day 10. Plasma renin activity, serum and urinary electrolytes, and body weight were unchanged during the study. Hence, low-dose heparin can inhibit aldosterone production. Patients receiving this treatment should be observed (during and after therapy) for impaired electrolyte homeostasis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740124     DOI: 10.1159/000167106

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  8 in total

1.  A low molecular weight heparin decreases plasma aldosterone in patients with primary hyperaldosteronism.

Authors:  N Cailleux; N Moore; H Levesque; H Courtois; M Godin
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Vascular remodeling and mineralocorticoids.

Authors:  K T Weber; Y Sun; S E Campbell; S H Slight; V K Ganjam
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

Review 3.  Drug-induced acid-base disorders.

Authors:  Daniel Kitterer; Matthias Schwab; M Dominik Alscher; Niko Braun; Joerg Latus
Journal:  Pediatr Nephrol       Date:  2014-11-05       Impact factor: 3.714

Review 4.  Potassium and anaesthesia.

Authors:  J E Tetzlaff; J F O'Hara; M T Walsh
Journal:  Can J Anaesth       Date:  1993-03       Impact factor: 5.063

Review 5.  Long-term anticoagulation. Indications and management.

Authors:  B M Stults; W H Dere; T H Caine
Journal:  West J Med       Date:  1989-10

Review 6.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

7.  Heparin-Induced Renal Tubular Acidosis Masquerading as Hyperkalemia in a SARS-CoV-2 (COVID-19) Patient: A Case Report.

Authors:  Vidya Baleguli; Riaz Mahmood; Martin Herrera; Erine Raybon-Rojas
Journal:  Cureus       Date:  2021-12-09

8.  Hyperkalemia: do you forget something?

Authors:  Matteo Landolfo; Maria Valeria Di Rosa; Luca Gasparotto; Antonio Marchese; Gianni Biolo
Journal:  Intern Emerg Med       Date:  2022-08-15       Impact factor: 5.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.